Quantitative analysis of cell-free DNA in ovarian cancer

Shao,Xuefeng; He,Yan; Ji,Min; Chen,Xiaofang; Qi,Jing; Shi,Wei; Hao,Tianbo; Ju,Shaoqing

doi:10.3892/ol.2015.3771

Quantitative analysis of cell-free DNA in ovarian cancer

Authors:
- Xuefeng Shao
- Yan He
- Min Ji
- Xiaofang Chen
- Jing Qi
- Wei Shi
- Tianbo Hao
- Shaoqing Ju
View Affiliations

Affiliations: Department of Clinical Laboratory, Maternity and Child Healthcare Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China, Department of Gynecology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830000, P.R. China, Department of Internal Medicine, Maternity and Child Healthcare Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China, Department of Gynecology, Maternity and Child Healthcare Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China, Department of Laboratory of Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226018, P.R. China
Published online on: September 30, 2015 https://doi.org/10.3892/ol.2015.3771
Pages: 3478-3482
Copyright: © Shao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association between cell-free DNA (cf-DNA) levels and clinicopathological characteristics of patients with ovarian cancer using a branched DNA (bDNA) technique, and to determine the value of quantitative cf‑DNA detection in assisting with the diagnosis of ovarian cancer. Serum specimens were collected from 36 patients with ovarian cancer on days 1, 3 and 7 following surgery, and additional serum samples were also collected from 22 benign ovarian tumor cases, and 19 healthy, non‑cancerous ovaries. bDNA techniques were used to detect serum cf‑DNA concentrations. All data were analyzed using SPSS version 18.0. The cf‑DNA levels were significantly increased in the ovarian cancer group compared with those of the benign ovarian tumor group and healthy ovarian group (P<0.01). Furthermore, cf‑DNA levels were significantly increased in stage III and IV ovarian cancer compared with those of stages I and II (P<0.01). In addition, cf‑DNA levels were significantly increased on the first day post‑surgery (P<0.01), and subsequently demonstrated a gradual decrease. In the ovarian cancer group, the area under the receiver operating characteristic curve of cf‑DNA and the sensitivity were 0.917 and 88.9%, respectively, which was higher than those of cancer antigen 125 (0.724, 75%) and human epididymis protein 4 (0.743, 80.6%). There was a correlation between the levels of serum cf‑DNA and the occurrence and development of ovarian cancer in the patients evaluated. bDNA techniques possessed higher sensitivity and specificity than other methods for the detection of serum cf‑DNA in patients exhibiting ovarian cancer, and bDNA techniques are more useful for detecting cf‑DNA than other factors. Thus, the present study demonstrated the potential value for the use of bDNA as an adjuvant diagnostic method for ovarian cancer.

View Figures

View References

1	Bhurgri Y, Shaheen Y, Kayani N, Nazir K, Ahmed R, Usman A, Bashir I, Setna F, Bhurgri A, Hasan SH and Zaidi SM: Incidence, trends and morphology of ovarian cancer in Karachi (1995–2002). Asian Pac J Cancer Prev. 12:1567–1571. 2011.PubMed/NCBI
2	Tinelli A, Vergara D, Martignago R, Leo G, Pisanò M and Malvasi A: An outlook on ovarian cancer and borderline ovarian tumors: Focus on genomic and proteomic findings. Curr Genomics. 10:240–249. 2009. View Article : Google Scholar : PubMed/NCBI
3	Sharifian A, Pourhoseingholi MA, Norouzinia M and Vahedi M: Ovarian cancer in Iranian women, a trend analysis of mortality and incidence. Asian Pac J Cancer Prev. 15:10787–10790. 2014. View Article : Google Scholar : PubMed/NCBI
4	Ohman AW, Hasan N and Dinulescu DM: Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer. Front Oncol. 4:3222014. View Article : Google Scholar : PubMed/NCBI
5	Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Nawa A, Kawai M, Nagasaka T and Kikkawa F: Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer. 105:1288–1294. 2011. View Article : Google Scholar : PubMed/NCBI
6	Zhen S, Bian LH, Chang LL and Gao X: Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. Mol Clin Oncol. 2:559–566. 2014.PubMed/NCBI
7	Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, et al: Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Cancer Epidemiol Biomarkers Prev. 23:1383–1393. 2014. View Article : Google Scholar : PubMed/NCBI
8	Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI
9	Salani R, Davidson B, Fiegl M, Marth C, Müller-Holzner E, Gastl G, Huang HY, Hsiao JC, Lin HS, Wang TL, et al: Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin Cancer Res. 13:5805–5809. 2007. View Article : Google Scholar : PubMed/NCBI
10	Fox BP and Kandpal RP: DNA-based assay for EPHB6 expression in breast carcinoma cells as a potential diagnostic test for detecting tumor cells in circulation. Cancer Genomics Proteomics. 7:9–16. 2010.PubMed/NCBI
11	Esposito A, Bardelli A, Criscitiello C, Colombo N, Gelao L, Fumagalli L, Minchella I, Locatelli M, Goldhirsch A and Curigliano G: Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. Cancer Treat Rev. 40:648–655. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhang Q, Hu G, Yang Q, Dong R, Xie X, Ma D, Shen K and Kong B: A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol. 130:132–139. 2013. View Article : Google Scholar : PubMed/NCBI
13	Manderson EN, Presneau N, Provencher D, Mes-Masson AM and Tonin PN: Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. Mol Carcinog. 34:78–90. 2002. View Article : Google Scholar : PubMed/NCBI
14	Tian F, Yip SP, Kwong DL, Lin Z, Yang Z and Wu VW: Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Cancer Epidemiol. 37:708–713. 2013. View Article : Google Scholar : PubMed/NCBI
15	Carpagnano GE, Costantino E, Palladino GP, Lacedonia D, Martinelli D, Orlando S and Foschino-Barbaro MP: Microsatellite alterations and cell-free DNA analysis: Could they increase the cytology sensitivity in the diagnosis of malignant pleural effusion? Rejuvenation Res. 15:265–273. 2012. View Article : Google Scholar : PubMed/NCBI
16	Portincasa P, Conti G and Chezzi C: Radio immune Western blotting: A possible solution to indeterminate conventional Western blotting results for the serodiagnosis of HIV infections. New Microbiol. 19:85–90. 1996.PubMed/NCBI
17	Wong IH: Qualitative and quantitative polymerase chain reaction-based methods for DNA methylation analyses. Methods Mol Biol. 336:33–43. 2006.PubMed/NCBI
18	Maehara Y, Anai H, Kusumoto T, Sakaguchi Y and Sugimachi K: Nick translation detection in situ of cellular DNA strand break induced by radiation. Am J Pathol. 134:7–10. 1989.PubMed/NCBI
19	Kalogianni DP, Litos IK, Christopoulos TK and Ioannou PC: Dipstick-type biosensor for visual detection of DNA with oligonucleotide-decorated colored polystyrene microspheres as reporters. Biosens Bioelectron. 24:1811–1815. 2009. View Article : Google Scholar : PubMed/NCBI
20	Cao Y, Ho DD, Todd J, Kokka R, Urdea M, Lifson JD, Piatak M Jr, Chen S, Hahn BH, Saag MS, et al: Clinical evaluation of branched DNA signal ampliﬁcation for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses. 11:353–361. 1995. View Article : Google Scholar : PubMed/NCBI
21	Liutkauskiene S, Janciauskiene R, Jureniene K, Grizas S, Malonyte R and Juozaityte E: Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients. BMC Cancer. 15:1052015. View Article : Google Scholar : PubMed/NCBI
22	Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W and Zhong XY: Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer. 8:1052009. View Article : Google Scholar : PubMed/NCBI
23	Zane M, Agostini M, Enzo MV, Casal Ide E, Del Bianco P, Torresan F, Merante Boschin I, Pennelli G, Saccani A, Rubello D, et al: Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF (V600E): A non-invasive tool panel for early detection of thyroid cancer. Biomed Pharmacother. 67:723–730. 2013. View Article : Google Scholar : PubMed/NCBI
24	Rass U: Resolving branched DNA intermediates with structure-specific nucleases during replication in eukaryotes. Chromosoma. 122:499–515. 2013. View Article : Google Scholar : PubMed/NCBI
25	Hao TB, Shi W, Shen XJ, Qi J, Wu XH, Wu Y, Tang YY and Ju SQ: Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 111:1482–1489. 2014. View Article : Google Scholar : PubMed/NCBI
26	Beiter T, Fragasso A, Hudemann J, Niess AM and Simon P: Short-term treadmill running as a model for studying cell-free DNA kinetics in vivo. Clin Chem. 57:633–666. 2011. View Article : Google Scholar : PubMed/NCBI